American Society of Hirudotherapy

Insulin Injection Lipohypertrophy

Investigational use for insulin injection-related lipohypertrophy nodules; no clinical study of leech therapy for them was identified.

Tier C — InvestigationalInvestigational: Limited human evidence exists (small trials, case series, or pilot studies). Use is investigational and should be considered carefully under clinician guidance.Last Updated: November 10, 2026 · ASH Editorial · based on the books

Patient Summary

Is this FDA-cleared for this use?
Not FDA-cleared for insulin-injection lipohypertrophy. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use here is Tier C investigational.
What evidence exists?
No published clinical study of leech therapy could be verified for this condition. Tier C (investigational). Evidence-based first-line management is site rotation, switching to a longer/finer needle each injection, and diabetes-educator review of injection technique.
Main risks
  • Bleeding from each bite site for 6 to 10 hours after the leech detaches
  • Iron-deficiency anemia from cumulative blood loss across multiple sessions
  • Aeromonas hydrophila wound infection from leech gut bacteria (uncommon outside reconstructive surgery, but possible)
  • Allergic reaction to leech saliva (rare; ranges from local itching to anaphylaxis)
  • Small Y-shaped bite marks or skin colour changes at the bite sites, which usually fade over weeks to months
  • Local pain, bruising, swelling, or itching for 1 to 3 days after each session
  • Unexpected swings in blood sugar if a session is placed too close to a recent insulin injection site
Who should not consider this
  • Patients with poorly controlled diabetes or severe hypoglycemia unawareness
  • Patients with active diabetic foot ulceration or any open injection-site wound
  • Anyone on blood thinners such as warfarin, apixaban, rivaroxaban, dabigatran or heparin (daily aspirin alone is not a contraindication: tell your doctor, who starts with fewer leeches)
  • People with hemophilia or any other inherited bleeding disorder
  • Patients with anemia
  • People with an active infection at the planned application site
  • Patients who are pregnant (leech therapy is not done during pregnancy) or breastfeeding (discuss it with your doctor)
What to ask your clinician
  • Has my injection technique been reviewed by a certified diabetes educator first?
  • Could rotating injection sites and changing needle length alone resolve the lumps?
  • How will my blood sugar be monitored on session days?
  • What is your plan if a leech bites close to a recent insulin site?
  • What scarring or hyperpigmentation should I expect on visible injection areas?
  • How will you confirm the lump is lipohypertrophy and not an injection-site lipoma or insulin amyloid?
When to seek urgent care
  • Bleeding from a bite site that soaks through more than one dressing per hour
  • Bleeding that continues more than 24 hours after the leech detached
  • Spreading redness, warmth, swelling, pus, or red streaks around any bite site
  • Fever over 38.0 C / 100.4 F, chills, or feeling suddenly unwell after a session
  • Hives, facial or tongue swelling, throat tightness, or any difficulty breathing
  • Sudden weakness, dizziness, fast heart rate, or fainting (possible severe blood loss)
  • Repeated severe low blood sugar (sweating, confusion, loss of consciousness) after a session

What this does NOT mean

  • It does not mean leech therapy is FDA-cleared for lipohypertrophy — the only FDA clearance for medicinal leeches is venous congestion in microsurgical reconstruction (K040187, June 2004).
  • It does not replace the proven first-line approach: site rotation, single-use needles, and re-education on insulin injection technique.
  • It does not address the underlying issue of repeatedly injecting into the same spot — without behavior change, the lumps will return.
  • It does not mean the lumps are dangerous in themselves — they mainly cause erratic insulin absorption and can be reversed by stopping injection into the area for several months.
  • It does not have any controlled-trial evidence to support efficacy.

Clinical Profile

Category
Dermatological
ICD-10
E65, L91.8, E11.69
Safety tier
Low

Evidence Summary

No clinical study or case report of leech therapy for insulin-injection lipohypertrophy was identified in PubMed, Europe PMC, ClinicalTrials.gov, Crossref, Russian-language sources or the Baskova and Isakhanyan (2004) monograph. The nearest finding is a 2025 Azerbaijani single-centre series (Farzali et al.) in which all 8 patients treated for lipoma were rated improved; lipoma is a benign fat tumour, not injection-site lipohypertrophy, so this cannot be transferred to this indication. Use is investigational and the rationale is mechanistic only. The proposed mechanism involves local extracellular-matrix remodeling. There is no evidence to support recommending it over the standard approach of injection-site rotation and education on injection technique. Caution: leeches must not be placed at sites of recent insulin injection because of subcutaneous bleeding risk. The presence of lipohypertrophy itself indicates suboptimal injection technique that warrants patient education.

Treatment specifics

How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: where the society's reference books describe a protocol, it is shown in the clinician view — switch the audience selector in the top bar to “Clinician”.)

Contraindications

  • Hemophilia or another bleeding disorder
  • Taking anticoagulants (blood thinners such as warfarin or heparin)
  • Anemia or suppressed blood formation
  • Low blood pressure, shock, collapse or fainting
  • Severe wasting (cachexia)
  • Intolerance of leeches or a history of severe allergic reactions
  • Pregnancy
  • Stomach or duodenal ulcer, erosive gastritis
  • Acute infectious disease or high fever
  • Severe unstable illness, markedly weakened immunity (for example during chemotherapy) or HIV infection
  • Drinking alcohol at the time of treatment
  • No consent from the patient
  • Active diabetic ulceration
  • Severe hypoglycemia unawareness

Related Conditions

This website provides educational information and does not constitute medical advice, diagnosis, or treatment recommendations. Medicinal leech therapy carries clinically meaningful risks and should be performed only by qualified clinicians under institutionally approved protocols. FDA 510(k) clearance for medicinal leeches is limited to specific indications; investigational and off-label discussions are labeled accordingly. For patient-specific guidance, consult a qualified healthcare provider.